N/A
Completed N=30
Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation
Liver Transplant Surgery
Source: ClinicalTrials.gov NCT05216991 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcomePrimary: Incidence of Postoperative Residual Weakness in the Recovery Room — 2; 0 Participants
Summary
The purpose of this research is to estimate the frequency of postoperative lasting muscle weakness in patients receiving Sugammadex after undergoing liver transplant surgery by using electromyographic device (EMG), such as TetraGraph.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Postoperative Residual Weakness in the Recovery Room |
2; 0 | — |
| SECONDARY ICU Admission |
2; 0 | — |
| SECONDARY Hospital Length of Stay |
6.1; 6.4 | — |
| SECONDARY Postoperative Pulmonary Complications |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients willing to participate and provide an informed consent.
- Patients undergoing primary liver transplantation.
Exclusion Criteria
- Patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
- Patients with systemic neuromuscular diseases such as myasthenia gravis.
- Patients with a known history of cerebrovascular accident (CVA).
- Patients undergoing repeat liver transplantation or concomitant pancreas/kidney transplantation at the time of liver transplantation.
- Patients admitted to the intensive care unit prior to liver transplantation.
Data sourced from ClinicalTrials.gov (NCT05216991). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.